Inhibition of Myeloperoxidase Activity in Cystic Fibrosis Sputum by Peptide Inhibitor of Complement C1 (PIC1)
- PMID: 28135312
- PMCID: PMC5279725
- DOI: 10.1371/journal.pone.0170203
Inhibition of Myeloperoxidase Activity in Cystic Fibrosis Sputum by Peptide Inhibitor of Complement C1 (PIC1)
Abstract
Myeloperoxidase is the major peroxidase enzyme in neutrophil granules and implicated in contributing to inflammatory lung damage in cystic fibrosis. Free myeloperoxidase is present in cystic fibrosis lung fluid and generates hypochlorous acid. Here we report a new inhibitor of myeloperoxidase activity, Peptide Inhibitor of Complement C1 (PIC1). Using TMB as the oxidizing substrate, PIC1 inhibited myeloperoxidase activity in cystic fibrosis sputum soluble fractions by an average of a 3.4-fold decrease (P = 0.02). PIC1 also dose-dependently inhibited myeloperoxidase activity in a neutrophil lysate or purified myeloperoxidase by up to 28-fold (P < 0.001). PIC1 inhibited myeloperoxidase activity similarly, on a molar basis, as the specific myeloperoxidase inhibitor 4-Aminobenzoic acid hydrazide (ABAH) for various oxidizing substrates. PIC1 was able to protect the heme ring of myeloperoxidase from destruction by NaOCl, assayed by spectral analysis. PIC1 incubated with oxidized TMB reversed the oxidation state of TMB, as measured by absorbance at 450 nm, with a 20-fold reduction in oxidized TMB (P = 0.02). This result was consistent with an antioxidant mechanism for PIC1. In summary, PIC1 inhibits the peroxidase activity of myeloperoxidase in CF sputum likely via an antioxidant mechanism.
Conflict of interest statement
The authors declare that no competing interests exist.
Figures





Similar articles
-
Peptide Inhibitor of Complement C1 Inhibits the Peroxidase Activity of Hemoglobin and Myoglobin.Int J Pept. 2017;2017:9454583. doi: 10.1155/2017/9454583. Epub 2017 Sep 10. Int J Pept. 2017. PMID: 29081812 Free PMC article.
-
Peptide Inhibitor of Complement C1 (PIC1) demonstrates antioxidant activity via single electron transport (SET) and hydrogen atom transfer (HAT).PLoS One. 2018 Mar 2;13(3):e0193931. doi: 10.1371/journal.pone.0193931. eCollection 2018. PLoS One. 2018. PMID: 29499069 Free PMC article.
-
Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum.J Lab Clin Med. 1988 Dec;112(6):711-20. J Lab Clin Med. 1988. PMID: 2848083
-
Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good.J Lab Clin Med. 2004 Sep;144(3):124-6. doi: 10.1016/j.lab.2004.05.014. J Lab Clin Med. 2004. PMID: 15478278 Review. No abstract available.
-
[Diagnostic possibilities of modern biochemical study of sputum from patients with cystic fibrosis (literature review).].Klin Lab Diagn. 2019;64(1):24-28. doi: 10.18821/0869-2084-2019-64-1-24-28. Klin Lab Diagn. 2019. PMID: 30912880 Review. Russian.
Cited by
-
Peptide Inhibitor of Complement C1 Inhibits the Peroxidase Activity of Hemoglobin and Myoglobin.Int J Pept. 2017;2017:9454583. doi: 10.1155/2017/9454583. Epub 2017 Sep 10. Int J Pept. 2017. PMID: 29081812 Free PMC article.
-
Myeloperoxidase in atrial fibrillation: association with progression, origin and influence of renin-angiotensin system antagonists.Clin Res Cardiol. 2020 Mar;109(3):324-330. doi: 10.1007/s00392-019-01512-z. Epub 2019 Jun 24. Clin Res Cardiol. 2020. PMID: 31236695
-
Peptide Inhibitor of Complement C1 (PIC1) demonstrates antioxidant activity via single electron transport (SET) and hydrogen atom transfer (HAT).PLoS One. 2018 Mar 2;13(3):e0193931. doi: 10.1371/journal.pone.0193931. eCollection 2018. PLoS One. 2018. PMID: 29499069 Free PMC article.
-
Peptide Inhibitor of Complement C1, RLS-0071, Reduces Zosteriform Spread of Herpes Simplex Virus Type 1 Skin Infection and Promotes Survival in Infected Mice.Viruses. 2021 Jul 22;13(8):1422. doi: 10.3390/v13081422. Viruses. 2021. PMID: 34452288 Free PMC article.
-
The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, and In Vivo and Ex Vivo Efficacy.Front Immunol. 2022 Feb 9;13:752315. doi: 10.3389/fimmu.2022.752315. eCollection 2022. Front Immunol. 2022. PMID: 35222367 Free PMC article. Review.
References
-
- Kettle AJ, Gedye CA, Winterbourn CC. Superoxide is an antagonist of antiinflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase. Biochemical pharmacology. 1993;45(10):2003–10. - PubMed
-
- Harrison JE, Schultz J. Studies on the chlorinating activity of myeloperoxidase. The Journal of biological chemistry. 1976;251(5):1371–4. - PubMed
-
- Mohammed JR, Mohammed BS, Pawluk LJ, Bucci DM, Baker NR, Davis WB. Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum. The Journal of laboratory and clinical medicine. 1988;112(6):711–20. - PubMed
-
- Thomson E, Brennan S, Senthilmohan R, Gangell CL, Chapman AL, Sly PD, et al. Identifying peroxidases and their oxidants in the early pathology of cystic fibrosis. Free radical biology & medicine. 2010;49(9):1354–60. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials